EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pre‐Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients

Roger M Li, Dino B A Tan iD, Chantalia Tedja, Wendy A Cooper, Helen E Jo, Christopher Grainge iD, Ian N Glaspole iD, Nicole Goh iD, Samantha Ellis, Peter M A Hopkins, Christopher Zappala, Gregory J Keir iD und 8 weitere

Respirology · 2025

DOI: 10.1111/resp.14894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respirology, 2025. Verfasst von Roger M Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Respiratory Health, Nedlands, Western Australia, Australia. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Matrix Metalloproteinase 7, Antifibrotic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lung Foundation Australia, Boehringer Ingelheim, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a poor prognosis. Antifibrotics slow the decline of pulmonary function after 12‐months, but limited studies have examined the role of circulatory biomarkers in antifibrotic treated IPF patients.

Methods

Serum from 98 IPF participants, from the Australian Idiopathic Pulmonary Fibrosis Registry were collected at four time‐points over 1 year post‐antifibrotic treatment and analysed as two separate cohorts. Patients were stratified as progressive, if they experienced ≥ 10% decline in FVC or ≥ 15% decline in DLCO or were deceased within 1 year of treatment initiation: or otherwise as stable. Ten molecules of interest were measured by ELISAs in patient serum.

Results

Baseline MMP7 levels were higher in progressive than stable patients in Cohort 1 ( p = 0.02) and Cohort 2 ( p = 0.0002). Baseline MMP7 levels also best differentiated progressive from stable patients (Cohort 1, AUC = 0.74, p = 0.02; Cohort 2, AUC = 0.81, p = 0.0003). Regression analysis of the combined cohort showed that elevated MMP7 levels predicted 12‐month progression (OR = 1.530, p = 0.010) and increased risk of overall mortality (HR = 1.268, p = 0.002). LASSO regression identified a multi‐biomarker panel (MMP7, ICAM‐1, CHI3L1, CA125) that differentiated progression more accurately than MMP7 alone. Furthermore, GAP combined with MMP7, ICAM‐1, CCL18 and SP‐D was more predictive of 3‐year mortality than GAP alone.

Conclusion

MMP7 along with a multi‐biomarker and GAP panel can predict IPF progression and mortality, with the potential for optimising management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisMatrix Metalloproteinase 7Antifibrotic AgentsHumansMaleFemaleAgedDisease ProgressionBiomarkersMiddle AgedPrognosisRegistriesAustraliaCohort Studies

Stichwörter der Autor:innen

biomarkerdisease progressionidiopathic pulmonary fibrosis

Substanzen

Matrix Metalloproteinase 7BiomarkersMMP7 protein, humanAntifibrotic Agents

Autor:innen und Institutionen

  • Institute for Respiratory Health, Nedlands, Western Australia, Australia.
  • University of Western Australia, Crawley, Western Australia, Australia.
  • Centre of Research Excellence in Pulmonary Fibrosis, Sydney, NSW, Australia.
  • Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • University of Sydney, Sydney, New South Wales, Australia.
  • Western Sydney University, Parramatta, New South Wales, Australia.

ORCID-Profile: Dino B A Tan, Christopher Grainge, Ian N Glaspole, Nicole Goh, Gregory J Keir, Paul N Reynolds, Sally Chapman, Darryl Knight, Tamera J Corte, Yuben P Moodley

Förderung

  • Lung Foundation Australia
  • Boehringer Ingelheim
  • National Health and Medical Research Council
  • Boehringer Ingelheim España

Zitieren

APA

Li, R. M., Tan, D. B. A., Tedja, C., Cooper, W. A., Jo, H. E., Grainge, C., Glaspole, I. N., Goh, N., Ellis, S., Hopkins, P. M. A., Zappala, C., Keir, G. J., Reynolds, P. N., Chapman, S., Walters, E. H., Knight, D., Baltic, S., Chih, H., Corte, T. J., & Moodley, Y. P. (2025). Pre‐Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients. Respirology. https://doi.org/10.1111/resp.14894

Vancouver

Li RM, Tan DBA, Tedja C, Cooper WA, Jo HE, Grainge C, et al. Pre‐Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients. Respirology. 2025. doi:10.1111/resp.14894

BibTeX
@article{Li2025,
  author = {Li, Roger M and Tan, Dino B A and Tedja, Chantalia and Cooper, Wendy A and Jo, Helen E and Grainge, Christopher and Glaspole, Ian N and Goh, Nicole and Ellis, Samantha and Hopkins, Peter M A and Zappala, Christopher and Keir, Gregory J and Reynolds, Paul N and Chapman, Sally and Walters, E Haydn and Knight, Darryl and Baltic, Svetlana and Chih, HuiJun and Corte, Tamera J and Moodley, Yuben P},
  title = {Pre‐Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients},
  journal = {Respirology},
  year = {2025},
  doi = {10.1111/resp.14894}
}
Kostenlos starten →